D-Glucitol,1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-
| Title | Journal |
|---|---|
| Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. | Chemico-biological interactions 20171101 |
| Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study. | Chemico-biological interactions 20171101 |
| Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model. | Chemico-biological interactions 20161025 |
| Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. | Clinical pharmacokinetics 20150701 |
| Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity. | Toxicologic pathology 20150101 |
| Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. | Chemico-biological interactions 20141205 |
| Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. | Chemico-biological interactions 20140925 |
| Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. | Expert opinion on drug metabolism & toxicology 20130601 |
| Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. | Current medical research and opinion 20120701 |
| Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. | Current medical research and opinion 20120701 |
| C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. | Bioorganic & medicinal chemistry 20120701 |
| A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. | Annals of medicine 20120601 |
| Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Diabetes, obesity & metabolism 20120601 |
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. | Diabetes care 20120601 |
| [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors]. | Orvosi hetilap 20120506 |
| Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. | PloS one 20120101 |
| Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. | Diabetes, obesity & metabolism 20110701 |
| A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition. | Postgraduate medicine 20110701 |
| New diabetes drugs go beyond insulin to flush out excess sugar. | Nature medicine 20110601 |
| Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. | Journal of medicinal chemistry 20110113 |
| Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. | Journal of medicinal chemistry 20100909 |